Vetoquinol SA

Equities

VETO

FR0004186856

Pharmaceuticals

Real-time Euronext Paris 05:44:32 2024-03-28 am EDT 5-day change 1st Jan Change
96.9 EUR -3.00% Intraday chart for Vetoquinol SA -1.22% -4.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vetoquinol SA Proposes Dividend CI
Vetoquinol SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
VETOQUINOL : Stifel downgrades its recommendation CF
Vetoquinol: 2% drop in annual sales CF
Vetoquinol SA Announces Sales Results for the Full Year 2023 CI
Vetoquinol Sa Announces Sales Results for the Third-Quarter and Nine Months of 2023 CI
Vetoquinol SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Vetoquinol Chairman to Step Down; CEO Named Successor MT
Vetoquinol SA Approves Dividend, Payable on 6 June 2023 CI
Vetoquinol SA Announces Executive Changes CI
Vetoquinol SA Announces Sales Results for the First Quarter of Financial Year 2023 CI
Global markets live: Shell, UBS, Nvidia, Coinbase, Block... Our Logo
Vetoquinol SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Vetoquinol SA Proposes Dividend CI
Vetoquinol SA Reports Sales Results for the Full Year Ended 2022 CI
Vetoquinol SA Announces Sales Results for the Third-Quarter and Nine Months of 2022 CI
Vetoquinol SA Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Vetoquinol Sa Reports Sales Results for the Second Quarter and First Six Months of 2022 CI
Global markets live: LVMH, GSK, Twitter, Blackrock, Walmart... Our Logo
Vetoquinol Reports Sales Results for the First Quarter of Fiscal Year 2022 CI
Vetoquinol Launches Felpreva®, A New Three-Monthly Feline Spot-On Parasiticide CI
Global markets live: Nvidia, Daimler, Credit Suisse, Alphabet, Uber... Our Logo
Vetoquinol SA Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Vetoquinol SA Proposes Dividend CI
Vetoquinol SAReports Sales Results for the Fourth Quarter and Full Year Ended December 31, 2021 CI
Chart Vetoquinol SA
More charts
Vetoquinol SA specializes in the research, development, production and marketing of veterinary drugs and products for pets (67.7% of net sales; dogs, cats, etc.) and livestock (32.3%; cattle, pigs, poultry, etc.). The group's activity is organized around 4 product families: - antibiotics; - anti-inflammatories; - cardiology and nephrology treatments; - other: anti-parasitics, vaccines, and nutritional products. At the end of 2022, the group had 5 production sites throughout the world. Net sales are distributed geographically as follows: Europe (46.7%), the Americas (36%) and Asia/Pacific (17.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
99.9 EUR
Average target price
107.1 EUR
Spread / Average Target
+7.18%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Vetoquinol SA - Euronext Paris
  4. News Vetoquinol SA
  5. Vetoquinol : Buys Canadian Rights to Profender Products for Cats